8.05
price up icon7.76%   0.58
 
loading
Altimmune Inc stock is traded at $8.05, with a volume of 4.73M. It is up +7.76% in the last 24 hours and up +17.01% over the past month. Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
See More
Previous Close:
$7.47
Open:
$7.61
24h Volume:
4.73M
Relative Volume:
1.77
Market Cap:
$585.35M
Revenue:
$409.00K
Net Income/Loss:
$-101.35M
P/E Ratio:
-4.9387
EPS:
-1.63
Net Cash Flow:
$-71.49M
1W Performance:
-15.44%
1M Performance:
+17.01%
6M Performance:
+0.12%
1Y Performance:
+206.08%
1-Day Range:
Value
$7.519
$8.4201
1-Week Range:
Value
$6.945
$9.70
52-Week Range:
Value
$2.4821
$14.84

Altimmune Inc Stock (ALT) Company Profile

Name
Name
Altimmune Inc
Name
Phone
(240) 654-1450
Name
Address
910 CLOPPER ROAD, GAITHERSBURG, MD
Name
Employee
59
Name
Twitter
Name
Next Earnings Date
2024-11-05
Name
Latest SEC Filings
Name
ALT's Discussions on Twitter

Compare ALT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
ALT 8.05 585.35M 409.00K -101.35M -71.49M -1.63
VRTX 451.23 115.74B 10.63B -479.80M -1.35B 13.33
REGN 743.35 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 591.82 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 248.79 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.14 24.49B 3.30B -501.07M 1.03B 11.54

Altimmune Inc Stock (ALT) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-29-24 Downgrade Guggenheim Buy → Neutral
Jan-24-24 Initiated Goldman Neutral
Mar-22-23 Downgrade Goldman Buy → Neutral
Dec-01-22 Initiated Goldman Buy
Dec-29-21 Resumed Jefferies Buy
Jun-02-21 Initiated H.C. Wainwright Buy
Feb-11-21 Initiated Guggenheim Buy
Dec-14-20 Initiated Jefferies Buy
Nov-12-20 Reiterated B. Riley Securities Buy
Sep-25-20 Initiated B. Riley FBR Buy
Aug-14-20 Initiated Evercore ISI Outperform
Jul-31-20 Initiated Piper Sandler Overweight
Jul-28-20 Initiated JMP Securities Mkt Outperform
Feb-24-20 Resumed ROTH Capital Buy
Jul-19-19 Initiated ROTH Capital Buy
Oct-09-17 Initiated Piper Jaffray Overweight
View All

Altimmune Inc Stock (ALT) Latest News

pulisher
Nov 18, 2024

FY2024 EPS Estimates for Altimmune Reduced by HC Wainwright - MarketBeat

Nov 18, 2024
pulisher
Nov 18, 2024

Altimmune, Inc. (NASDAQ:ALT) Receives $20.00 Consensus Target Price from Analysts - MarketBeat

Nov 18, 2024
pulisher
Nov 16, 2024

(ALT) Trading Report - Stock Traders Daily

Nov 16, 2024
pulisher
Nov 16, 2024

Altimmune, Inc. Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease at The Liver Meeting 2024 - Marketscreener.com

Nov 16, 2024
pulisher
Nov 15, 2024

Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024 - The Manila Times

Nov 15, 2024
pulisher
Nov 15, 2024

Altimmune's Pemvidutide Shows 68.5% Liver Fat Reduction in Phase 1b Trial Results | ALT Stock News - StockTitan

Nov 15, 2024
pulisher
Nov 15, 2024

What is B. Riley's Forecast for Altimmune FY2024 Earnings? - MarketBeat

Nov 15, 2024
pulisher
Nov 14, 2024

AMERIPRISE FINANCIAL INC's Strategic Acquisition in Altimmune Inc - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

B. Riley Weighs in on Altimmune's Q1 Earnings (NASDAQ:ALT) - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

Altimmune (NASDAQ:ALT) Given Buy Rating at HC Wainwright - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

Altimmune Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 14, 2024
pulisher
Nov 13, 2024

Altimmune: Pemvidutide As MASH Drug Could Provide Competitive Edge (NASDAQ:ALT) - Seeking Alpha

Nov 13, 2024
pulisher
Nov 13, 2024

Altimmune Unusual Options Activity For November 13 - Benzinga

Nov 13, 2024
pulisher
Nov 13, 2024

Altimmune’s Pemvidutide Gains Momentum: Sizeable TAMs In Obesity And Liver Health (ALT) - Seeking Alpha

Nov 13, 2024
pulisher
Nov 13, 2024

Altimmune provided key pipeline updates with Q3 report, says B. Riley - TipRanks

Nov 13, 2024
pulisher
Nov 13, 2024

Altimmune, Inc. (NASDAQ:ALT) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 13, 2024
pulisher
Nov 13, 2024

UBS Initiates Coverage of Altimmune (ALT) with Buy Recommendation - Nasdaq

Nov 13, 2024
pulisher
Nov 13, 2024

GSA Capital Partners LLP Sells 148,530 Shares of Altimmune, Inc. (NASDAQ:ALT) - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

Earnings call: Altimmune reports progress on pemvidutide trials, financials - Investing.com India

Nov 13, 2024
pulisher
Nov 13, 2024

Earnings call: Altimmune reports progress on pemvidutide trials, financials By Investing.com - Investing.com Canada

Nov 13, 2024
pulisher
Nov 13, 2024

Altimmune Inc (ALT) Q3 2024 Earnings Call Highlights: Strategic FDA Alignment and Expanding R&D Investments - GuruFocus.com

Nov 13, 2024
pulisher
Nov 13, 2024

Altimmune Inc (ALT) Q3 2024 Earnings Call Highlights: Strategic FDA Alignment and Expanding ... - Yahoo Finance

Nov 13, 2024
pulisher
Nov 13, 2024

Altimmune (ALT) Stock Soars 27%: Phase 2 Data On Obesity Drug Ignites Market Optimism - Barchart

Nov 13, 2024
pulisher
Nov 12, 2024

Altimmune Reports Q3 2024 Financial Results and Advances Drug Pipeline - TipRanks

Nov 12, 2024
pulisher
Nov 12, 2024

Altimmune Stock Rallies 30% on Updates - citybiz

Nov 12, 2024
pulisher
Nov 12, 2024

Altimmune stock rallies 30% on business updates, UBS buy rating - MSN

Nov 12, 2024
pulisher
Nov 12, 2024

Altimmune stock rallies 30% on business updates, UBS buy rating (NASDAQ:ALT) - Seeking Alpha

Nov 12, 2024
pulisher
Nov 12, 2024

Altimmune, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 12, 2024
pulisher
Nov 12, 2024

Traders Purchase Large Volume of Altimmune Call Options (NASDAQ:ALT) - MarketBeat

Nov 12, 2024
pulisher
Nov 12, 2024

Altimmune Inc Reports Q3 2024 Results: GAAP EPS of -$0.32 Beats Estimates, Revenue at $5,000 - GuruFocus.com

Nov 12, 2024
pulisher
Nov 12, 2024

Altimmune Appoints Gregory Weaver as CFO for Growth - TipRanks

Nov 12, 2024
pulisher
Nov 12, 2024

UBS Group Initiates Coverage on Altimmune (NASDAQ:ALT) - MarketBeat

Nov 12, 2024
pulisher
Nov 12, 2024

Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update - Yahoo Finance

Nov 12, 2024
pulisher
Nov 11, 2024

Altimmune Appoints Greg Weaver as CFO - citybiz

Nov 11, 2024
pulisher
Nov 11, 2024

Altimmune Appoints Chief Financial Officer - Contract Pharma

Nov 11, 2024
pulisher
Nov 11, 2024

Altimmune says ‘something raised attention of FDA’ - TipRanks

Nov 11, 2024
pulisher
Nov 11, 2024

Altimmune appoints Greg Weaver as CFO - TipRanks

Nov 11, 2024
pulisher
Nov 11, 2024

Altimmune Names Greg Weaver Chief Financial Officer - MarketWatch

Nov 11, 2024
pulisher
Nov 11, 2024

S&P 500 Index (INX) QuotePress Release - The Globe and Mail

Nov 11, 2024
pulisher
Nov 11, 2024

Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Nov 11, 2024
pulisher
Nov 11, 2024

Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer - The Manila Times

Nov 11, 2024
pulisher
Nov 11, 2024

TSX Communication Services Capped Index (TTTS) QuotePress Release - The Globe and Mail

Nov 11, 2024
pulisher
Nov 11, 2024

Altimmune, Inc. Appoints Greg Weaver as Chief Financial Officer - Marketscreener.com

Nov 11, 2024
pulisher
Nov 08, 2024

How Altimmune Could Grab a Big Chunk of the GLP-1 Market - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

Eli Lilly and Company (LLY-N) QuotePress Release - The Globe and Mail

Nov 08, 2024
pulisher
Nov 08, 2024

Institutional investors control 59% of Altimmune, Inc. (NASDAQ:ALT) and were rewarded last week after stock increased 11% - Simply Wall St

Nov 08, 2024
pulisher
Nov 08, 2024

Altimmune advances obesity treatment into Phase 3 trials By Investing.com - Investing.com South Africa

Nov 08, 2024
pulisher
Nov 07, 2024

Altimmune, FDA agree on efficacy measures for phase 3 trial of pemvidutide - Seeking Alpha

Nov 07, 2024
pulisher
Nov 07, 2024

Altimmune advances obesity treatment into Phase 3 trials - Investing.com India

Nov 07, 2024
pulisher
Nov 07, 2024

Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity - The Manila Times

Nov 07, 2024
pulisher
Nov 07, 2024

Altimmune Advances Obesity Drug: FDA Greenlights Major Phase 3 Program Design | ALT Stock News - StockTitan

Nov 07, 2024

Altimmune Inc Stock (ALT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$71.05
price up icon 0.69%
$18.62
price down icon 6.90%
$36.94
price down icon 0.94%
$364.33
price up icon 1.00%
$194.26
price up icon 3.46%
$102.14
price down icon 4.00%
Cap:     |  Volume (24h):